FULVESTRANT
Diffuse Midline Glioma, H3 K27M-Mutant
Nationwide Children's HospitalSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Diffuse Midline Glioma, H3 K27M-Mutant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole Nationwide Children's Hospital | Phase 2 | B |
Ribociclib Nationwide Children's Hospital | Phase 2 | B |
LEUPROLIDE Nationwide Children's Hospital | Phase 2 | B |
Zoladex Nationwide Children's Hospital | Phase 2 | B |
Olutasidenib Rigel Pharmaceuticals | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →